Position 1: Ischemia and Viability Testing Are Overrated – Clinical Judgement Should Guide Patient Management
We Recommend
Disclosures
Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:
- Royalty/Intellectual Property Rights - Asahi
- Consultant Fee/Honoraria/Speaker's Bureau - Asahi; Boston Scientific Corporation; Medtronic; Teleflex
- Equity/Stock(s)/Options - Rampart IC